Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high262.00 04/10/16
52 week low82.75 04/03/16
52 week change 79.50 (71.95%)
4 week volume622,843 28/01/17

Media for (SUMM)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Summit Therapeutics plc : Exercise of Warrants

Summit Therapeutics plc: Exercise of Warrants Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF WARRANTS Oxford, UK, 23 February 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...

Summit to take part in investor conferences

Summit Therapeutics has announced that company management will participate in three upcoming investor conferences ...

Summit Therapeutics to Participate in February Investor Conferences

Summit Therapeutics to Participate in February Investor Conferences Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PARTICIPATE IN FEBRUARY INVESTOR CONFERENCES Oxford, UK, 2 February 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development c...

Summit outlines Phase 3 programme for ridinilazole

Summit Therapeutics has outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory ...

Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole

Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT OUTLINES PHASE 3 PROGRAMME FOR NOVEL CDI ANTIBIOTIC RIDINILAZOLE FOLLOWING FDA AND EMA REGULATORY MEETINGS Oxford, UK, 1 February 2017 - Summit Therapeutics plc (AIM...

Summit Therapeutics plc : Holding(s) in Company

Summit Therapeutics plc: Holding(s) in Company TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii SUMMIT THERAPEUTICS PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An...

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit", the "Company" or the "Group") EXERCISE OF SHARE OPTIONS Oxford, UK, 19 January 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infec...

Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development

Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development Summit Therapeutics plc ('Summit', 'Company' or the 'Group') SUMMIT APPOINTS DR DAVID ROBLIN AS CHIEF OPERATING OFFICER AND PRESIDENT OF RESEARCH & DEVELOPMENT Oxford, UK, 18 January 2017 - Summit Therapeutics plc (A...

Fundamental DataMore

EPS-41
Dividend yield0 %

Latest discussion posts More

  • RNS Ridinilazole CDI

    Good RNS today to push sp up around 13% to #1.90. The FDA and EMA have agreed with Summit the parameters for the Phase 3 trials. Essentially the authorities want the Phase 3 ...
    1-Feb-2017
    bobsson
  • That`s better

    Great to see sp recovering from the 140s pre new year. Expect to see C dif deal before end of H1. Progress on DMD scientific or anecdotal could come at any time by end of H1. ...
    24-Jan-2017
    bobsson
  • Wow!

    At this rate SUMM sp will end 2017 lower than it started. AFAIK the drivers for 2017 will be the C-Dif Riddy drug comparison study as against Fidoximicin and that should be Q1 ...
    13-Dec-2016
    bobsson

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
LLOYDS GRP.20%
RANGE RES.18%
ROYAL BANK SCOT15%
SIRIUS MINERALS15%
BARCLAYS12%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM